Somatic monoallelic single nucleotide variants in the genes that encode isocitrate dehydrogenase (IDH) 1 and 2 are found in a large subset of diffusely infiltrating gliomas and subsets of acute ...

Biomarker testing, particularly IDH1 status, should be linked to diagnosis refinement, prognostication, and treatment selection, with explicit discussion of result implications and any need for ...

IDH-mutant glioma, caused by abnormalities in a specific gene (IDH), is the most common malignant brain tumor among young adults under the age of 50. It is a refractory brain cancer that is difficult ...

Voranigo is rapidly adopted for IDH-mutated glioma, addressing unmet needs and shifting towards earlier intervention. Retrospective analysis identified 520 patients treated with Voranigo, with 41% ...

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer IDH-mutant brainstem gliomas have a characteristic clinical and radiographic phenotype.

CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.

Efficacy and safety of bevacizumab in combination with radiotherapy and temozolomide in patients with glioblastoma: A meta-analysis and meta-regression of randomized controlled trials. This is an ASCO ...

IDH-mutant, grade 3 astrocytoma is a serious condition, and many of these tumors return even after aggressive, upfront treatment. By adding a newer, targeted therapy aimed at the underlying IDH ...

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first ...